Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Engineering
Response Of A Sage Grouse Breeding Population To Fire In Southeastern Idaho, John W. Connelly, Kerry P. Reese, Richard A. Fischer, Wayne L. Wakkinen
Response Of A Sage Grouse Breeding Population To Fire In Southeastern Idaho, John W. Connelly, Kerry P. Reese, Richard A. Fischer, Wayne L. Wakkinen
US Army Research
Prescribed burning is a common method to eliminate sagebrush (Artemisia spp.) and has been suggested as a tool to enhance the habitat of sage grouse (Centrocercus urophasianus). Effects of this practice on sage grouse have not been evaluated rigorously. We studied effects of prescribed fire on lek (traditional breeding display areas) attendance by male sage grouse occupying low-precipitation (<26 cm) sagebrush habitats in south- eastern Idaho from 1986 through 1994. During the preburn period (1986-89), average declines for male attendance were 48% and 46% for treatment and control leks, respectively. Lek counts were similar for treatment and control leks during the preburn years (G-test, 0.25>P>0.10). During the postburn period (1990-94), male attendance at treatment leks declined 90% and control leks declined 63%. Although declines were similar between treatment and control leks during the preburn period, postburn declines were greater for treatment …
Development Of Vaccines For Prevention Of Botulism, Michael P. Byrne, Leonard A. Smith
Development Of Vaccines For Prevention Of Botulism, Michael P. Byrne, Leonard A. Smith
US Army Research
Botulism is a potentially lethal disease caused by one of seven homologous neurotoxic proteins usually produced by the bacterium, Clostridium botulinum. This neuromuscular disorder occurs through an exquisite series of molecular events, ultimately ending with the arrest of acetylcholine release and hence, flaccid paralysis. The development of vaccines that protect against botulism dates back to the 1940s. Currently, a pentavalent vaccine that protects against BoNT serotypes A-E and a separate monovalent vaccine that protects against BoNT serotype F are available as Investigational New Drugs. However, due to the numerous shortcomings associated with the toxoid vaccines, several groups have efforts …